Bioreclamation and CelsisIVT Combine to Create BioreclamationIVT
News Aug 29, 2013
Bioreclamation Group, Inc. announced it has acquired Celsis In Vitro Technologies (“CelsisIVT”), a division of Celsis International Ltd. and a provider of in vitro products for the study of drug metabolism and toxicity. Brown Gibbons Lang & Company represented the Maryland-based CelsisIVT in the transaction. Terms of the deal were not disclosed.
The two companies will combine to become BioreclamationIVT, creating a one-stop shop offering a complete range of biological tools needed to pursue new drug discovery and development. The combined Companies’ highly specialized products enable researchers to better understand the pharmacokinetics and metabolism of newly discovered compounds. BioreclamationIVT’s sophisticated sourcing and exceptional quality control processes help reduce the time and cost of screening drug compounds in early-stage drug discovery and development.
Blood-vessel-on-a-chip Provides Insight into Novel Anti-Inflammatory Drug CandidateNews
Researchers have discovered that synthetic APC-mimicking small molecules called “parmodulins” provide anti-inflammatory and anti-thrombotic protection to endothelial cells on par with APC’s without interfering with normal blood clotting and coagulation, making them attractive new drug candidates.READ MORE
Brian Berridge Set to Manage National Toxicology ProgramNews
The National Toxicology Program (NTP) has named Brian Berridge, D.V.M., Ph.D., as its new Associate Director. Berridge, formerly of GlaxoSmithKline, will oversee day-to-day operations as NTP coordinates toxicology research and testing across nine different federal agencies.READ MORE
Arsenic-Tainted Drinking Water May Increase Diabetes RiskNews
A new study reports that chronic exposure to arsenic interferes with insulin secretion in the pancreas, which may increase the risk of diabetes.READ MORE